Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000367 | 0.88 | BRAF (0.65) | RXFP1LCKMAPTMEN1KMT2A | |
| SCHEMBL17103384 | 0.84 | RXFP1 (0.81) | RXFP1MAPTMEN1KMT2APOLB | |
| SCHEMBL5002647 | 0.83 | LCK (0.67) | RXFP1LCKMAPTMEN1KMT2A | |
| SCHEMBL2851288 | 0.81 | MEN1 (0.75) | RXFP1MAPTMEN1KMT2APOLB | |
| SCHEMBL8710692 | 0.80 | RXFP1 (0.81) | RXFP1TRPV1MAPTMEN1KMT2A | |
| SCHEMBL4440208 | 0.80 | RAF1 (0.65) | RXFP1LCKMAPTMEN1KMT2A | |
| SCHEMBL18146433 | 0.80 | RORC (0.70) | RXFP1TRPV1MAPTMEN1KMT2A | |
| SCHEMBL28809368 | 0.80 | MEN1 (0.64) | RXFP1MAPTMEN1KMT2APOLB | |
| SCHEMBL4434896 | 0.79 | RXFP1 (0.63) | RXFP1LCKMAPTMEN1KMT2A | |
| SCHEMBL28330872 | 0.78 | RXFP1 (0.69) | RXFP1TRPV1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2121692-B1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | RXFP1 4578/4885LCK 50/4885TRPV1 3429/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | RXFP1 4079/4885LCK 34/4885TRPV1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.